Sanotize is recruiting for a COVID trial in the provinces of Quebec and Ontario.   

NORSTM for COVID-19

SaNOtize is working diligently with Health Canada and the FDA to obtain approval for the emergency release of a preventative treatment for healthcare workers and high risk individuals exposed to SARS-CoV-2.


NORS2791 for Treatment of Acne

NORS2791 product candidate will be a topical formulation of NORSTM for the treatment of acne, a chronic, inflammatory skin condition. This formulation will be delivered as a topical gel.


NORS4002 for Treatment of Sinusitis

The SaNOtize team believes that NORSTM may be especially effective as a nasal lavage for treating sinusitis, regardless of infectious etiology. In vitro studies have shown the efficacy of NO and NO delivered through NORSTM against many strains of bacteria, viruses and fungi associated with sinusitis.


NORS0791 for Treatment of Onychomycosis

NORS2791 product candidate will be a topical formulation of NORSTM for the treatment of onychomycosis, a fungal infection of the toenail. For these patients, NORSTM will be delivered via a specially designed bandage containing a NO releasing gel.


NORS1002 for Treatment and Prevention of the Cold & Flu

Our in-vitro studies indicate that NORSTM may be effectively delivered as nasal spray to prevent the common cold and flu.


NORS6491 for Treatment of Athlete’s Foot

The SaNOtize team has completed in-vitro studies showing the ability of NORSTM to eradicate common fungi associated with athlete’s foot.

logged in